About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker RYTM · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study of Setmelanotide in Patients With Prader-Willi Syndrome
NCT06772597 · Prader-Willi Syndrome, Obesity
Setmelanotide
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 2Active, not recruiting18Nov 3, 2026Registry ↗
Nov 12, 2026EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
NCT05093634 · Obesity, Genetic Obesity
Setmelanotide, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 3Completed296Dec 19, 2025Registry ↗
Oct 30, 2026A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
NCT06046443 · Hypothalamic Obesity
Bivamelagon, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 2Completed28Feb 9, 2026Registry ↗
Oct 9, 2026A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
NCT06239116 · Hypothalamic Obesity, Prader-Willi Syndrome
Part A: RM-718 or placebo (matched to specific RM-718 dose…
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 1/2Active, not recruiting111May 7, 2027Registry ↗
Aug 10, 2026A Trial of Setmelanotide in Acquired Hypothalamic Obesity
NCT05774756 · Hypothalamic Obesity
Setmelanotide, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 3Active, not recruiting143Mar 18, 2025Registry ↗
Jul 15, 2026Open-Label Extension Study of Setmelanotide
NCT06596135 · Obesity Associated With Defects in Leptin-melanocortin Path…
Setmelanotide
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 3Completed28Jun 24, 2026Registry ↗
Feb 12, 2026A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546 · Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency…
Setmelanotide, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 3Recruiting39Mar 13, 2027Registry ↗
Feb 10, 2026A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
NCT07156578 · Hypothalamic Obesity
Bivamelagon
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 2Enrolling by invitation25Apr 15, 2028Registry ↗
Jul 2, 2025DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-…
NCT04963231 · Genetic Obesity
Setmelanotide, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 2Completed164Aug 4, 2023Registry ↗
May 31, 2025Long Term Extension Trial of Setmelanotide
NCT03651765 · Obesity Associated With Defects in Leptin-melanocortin Path…
Setmelanotide
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 2/3Completed205Jan 9, 2025Registry ↗
Feb 7, 2025Open-Label Study of Setmelanotide in Hypothalamic Obesity
NCT04725240 · Hypothalamic Obesity
Setmelanotide
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 2Completed18Jun 28, 2022Registry ↗
Nov 27, 2024Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
NCT04966741 · Bardet-Biedl Syndrome, POMC Deficiency Obesity
Setmelanotide
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 3Completed12Sep 18, 2023Registry ↗
Nov 26, 2024Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Def…
NCT05194124 · Bardet-Biedl Syndrome, POMC Deficiency
Setmelanotide 2 mg, Setmelanotide 2.5 mg
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 3Completed19Oct 19, 2023Registry ↗
May 3, 2024Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
NCT05046132 · Healthy
Setmelanotide, Moxifloxacin
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 4Completed77Apr 7, 2022Registry ↗
Dec 1, 2023Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and…
NCT03746522 · Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 3Completed52Nov 16, 2020Registry ↗
Sep 21, 2023Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
NCT02896192 · Pro-opiomelanocortin (POMC) Deficiency Obesity
Setmelanotide, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 3Completed15May 25, 2020Registry ↗
Aug 18, 2023Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
NCT03013543 · Genetic Obesity, Obesity
Setmelanotide
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 2Completed213Mar 1, 2022Registry ↗
Aug 14, 2023Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
NCT01749137 · Overweight
Setmelanotide, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 2Completed74Sep 28, 2013Registry ↗
Aug 7, 2023Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
NCT02041195 · Overweight and Obesity
Setmelanotide, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 1/2Completed99Aug 2014Registry ↗
Jul 27, 2023Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With…
NCT02311673 · Prader-Willi Syndrome
Setmelanotide, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 2Completed40Oct 26, 2016Registry ↗
May 23, 2023Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
NCT03287960 · Leptin Receptor Deficiency Obesity
Setmelanotide, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 3Completed15Sep 25, 2020Registry ↗
Nov 15, 2022Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
NCT02849977 · Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilis…
RYTM
Rhythm Pharmaceuticals, Inc.
—Completed5,966Jun 9, 2020Registry ↗
Aug 10, 2022An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)
NCT05183802 · Bardet-Biedl Syndrome (BBS), Obesity
Setmelanotide, administered subcutaneously [SC], once daily.
RYTM
Rhythm Pharmaceuticals, Inc.
—Approved for marketing——Registry ↗
Jan 4, 2022Setmelanotide in a Single Patient With Partial Lipodystrophy
NCT03262610 · Hypertriglyceridemia, Obesity
Setmelanotide
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 2Completed1Jan 31, 2018Registry ↗
Jun 30, 2021A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees…
NCT04348175 · Renal Insufficiency
Setmelanotide
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 1Completed32Apr 17, 2021Registry ↗
Jun 30, 2021An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic…
NCT03621007 · POMC Deficiency Obesity, PCSK1 Deficiency Obesity
RYTM
Rhythm Pharmaceuticals, Inc.
—Completed8Jan 22, 2021Registry ↗
May 4, 2021The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry
NCT03479437 · Genetic Forms of Extreme Obesity
RYTM
Rhythm Pharmaceuticals, Inc.
—Completed303Dec 1, 2020Registry ↗
Apr 20, 2017Effects of RM-493 on Energy Expenditure in Obese Individuals
NCT01867437 · Obesity, Morbid Obesity
Placebo, RM-493
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 1Completed15Mar 2014Registry ↗
May 1, 2015Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administere…
NCT02431442 · Overweight, Obese
RM-493, Placebo
RYTM
Rhythm Pharmaceuticals, Inc.
Phase 1Completed57Jan 2014Registry ↗

29 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:06 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances